

## Formulation of Extended-Release Ranolazine Tablet and Investigation Its Stability in the Accelerated Stability Condition at 40°C and 75% Humidity

**Authors :** Farzad Khajavi, Farzaneh Jalilfar, Faranak Jafari, Leila Shokrani

**Abstract :** Formulation of Ranolazine in the form of extended-release tablet in 500 mg dosage form was performed using Eudragit L100-55 as a retarding agent. Drug-release profiles were investigated in comparison with the reference Ranexa extended-release 500 mg tablet.  $F_2$  and  $f_1$  were calculated as 64.16 and 8.53, respectively. According to Peppas equation, the release of drug is controlled by diffusion ( $n=0.5$ ). The tablets were put into accelerated stability conditions (40 °C, 75% humidity) for 3 and 6 months. The dissolution release profiles and other physical and chemical characteristics of the tablets confirmed the robustness and stability of formulation in this condition.

**Keywords :** drug release, extended-release tablet, ranolazine, stability

**Conference Title :** ICDD 2020 : International Conference on Drug Discovery

**Conference Location :** Toronto, Canada

**Conference Dates :** September 21-22, 2020